$AMGN

AI Analysis

Generated on May 18, 2026

AI Score
74/ 100
Buy$AMGN

Amgen Inc.

$AMGNNASDAQHealthcareLarge-Cap

Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide focusing on inflammation, oncology, and cardiovascular disease.

Market Cap
$165B
Revenue (TTM)
$34.5B
+18.5%
Net Income (TTM)
$6.8B
+12.2%
EPS (TTM)
$12.52
P/E Ratio
24.5
Dividend Yield
2.8%
52-Week Range
$265-$335
Beta
0.58
Dimension Scores
Fundamental
78
Technical
70
Sentiment
74
Risk / Reward
74
Momentum
68
FundTechSentRiskMome
Financial Health
Profitability
78moderate
Growth
75moderate
Liquidity
72moderate
Solvency
62moderate
Efficiency
76moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $AMGN

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.